Drugs / Microgynon
last change Jul 2024 re-read 2 minutes ago

Microgynon

Developed for
endometriosis
Investigated by
Bayer · Novo Nordisk A/S · Boehringer Ingelheim · Eli Lilly and Company · GlaxoSmithKline · Hoffmann-La Roche
+1 more · Merck KGaA, Darmstadt, Germany

Trials 9 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06354257 Apr → Jul 2024 tuberculosis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT05153564 Dec 2021 → Aug 2022 type 2 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded
Phase 1 NCT03745144 Jan 2019 → Sep 2022 relapsing-remitting multiple sclerosis Merck KGaA, Darmstadt, Germany Completed No outcome recorded
Phase 1 NCT03210246 Jul 2017 → Jun 2018 Bayer Completed No outcome recorded
Phase 1 NCT02845219 Jul → Dec 2016 type 2 diabetes mellitus Novo Nordisk A/S Completed No outcome recorded
Phase 1 NCT02159326 Jun 2014 → Mar 2015 Bayer Completed No outcome recorded
Phase 1 NCT01941615 Nov 2013 → Jan 2014 Boehringer Ingelheim Terminated No outcome recorded
Phase 1 NCT01896726 Jul → Oct 2013 Eli Lilly and Company Completed No outcome recorded
Phase 1 NCT01615354 Jul 2012 → Jan 2013 Hoffmann-La Roche Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02385448 Comparator Feb 2015 → Feb 2017 endometriosis The University of Hong Kong Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as Microgynon ClinicalTrials.gov intervention name — accepted as the source's own label NCT02845219
9

NCT06354257

NCT01615354

NCT03210246

NCT02159326

NCT01941615

NCT02385448

NCT03745144

NCT01896726

NCT05153564

Route Oral “Multiple oral doses” NCT01615354